Anlotinib after progression for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether continuing anlotinib (a targeted therapy that stops tumor blood vessel growth) or switching to another treatment after the first round stops working can help people with advanced lung cancer. It is for patients with non-small cell or small cell lung cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (like squamous or adenocarcinoma) or extensive-stage small cell lung cancer
- Your cancer has no driver gene mutations (like EGFR or ALK)
- You have been treated with anlotinib for at least 4 months and then the cancer continued to grow
- You had a scan within 90 days before starting the next treatment after anlotinib
- You have not had other anti-angiogenic drugs (like bevacizumab or sunitinib) before or after your first anlotinib treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—lomustine (a chemotherapy) and anlotinib (a targeted therapy)—in patients whose small cell lung cancer has stopped responding to at least two previous treatment regimens. The goal is to see if this combination can slow or stop the cancer's growth.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial looks at whether adding a targeted therapy called anlotinib to immunotherapy maintenance can help people with extensive-stage small cell lung cancer who have already completed 4-6 cycles of standard chemoimmunotherapy without the cancer getting worse.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.